Review synthesizes evidence on neurofilament light chain's diagnostic, prognostic, and therapeutic role in neurological disorders, highlighting limitations.
Key Points
This review aims to evaluate the role of neurofilament light chain as a biomarker in diagnosing and monitoring neurological disorders.
Synthesis of current evidence regarding neurofilament light chain and its interactions with glial fibrillary acidic protein and other biomarkers.
Discussion of diagnostic and prognostic applications in conditions like multiple sclerosis, Alzheimer's disease, ALS, and Parkinson's disease.
Identification of limitations due to physiological variability and the proposed integration with multimodal biomarkers.
Neurofilament light chain levels correlate with neuroaxonal injury and predict disability in multiple sclerosis and neurodegeneration in Alzheimer's disease.
Elevated levels are indicative of disease severity and progression in amyotrophic lateral sclerosis, Parkinson's disease, and traumatic brain injury.
Combining neurofilament light chain with other biomarkers, such as GFAP, enhances diagnostic accuracy and may differentiate between disorders.